Study on the Regulatory Effect of Realgar for External Use on Epithelial Mesenchymal Transformation in Triple Negative Breast Cancer
-
摘要:
目的 研究中药雄黄外用对三阴性乳腺癌上皮间质转化的作用及调控机制。 方法 采用人三阴性乳腺癌MDA-MB-231细胞构建裸鼠人乳腺癌移植瘤模型后, 将裸鼠随机分为模型组、雄黄外用组、卡培他滨片组, 干预6周后取材。通过HE染色、免疫组化、Western blot、qPCR等方法观察雄黄外用对乳腺癌肿瘤上皮间质转化的调控作用, 同时对动物血常规, 肝、肾功能指标进行检测。 结果 雄黄外用可使乳腺癌组织出现一定程度的坏死, 抑瘤率为30.2%;与模型组比较, 雄黄外用组裸鼠肝、肾功能及血常规检测等未见明显异常; 肿瘤组织免疫组化结果提示, 雄黄外用可增强上皮钙黏蛋白(E-cadherin)表达, 降低波形蛋白(Vimentin)表达; Western blot和qPCR结果提示: 与模型组比较, 雄黄外用可上调肿瘤组织中E-cadherin表达, 减弱Vimentin、Twist1、TGF-β1的表达, 差异具有统计学意义(P < 0.05)。 结论 雄黄外用可抑制人三阴性乳腺癌移植瘤在体生长, 其机制与增强E-cadherin表达, 降低Vimentin、Twist1、TGF-β1的表达, 实现对乳腺癌上皮间质转化的调控相关。 Abstract:OBJECTIVE To investigate the regulatory effect of realgar for external use on epithelial mesenchymal transformation in triple negative breast cancer. METHODS Human breast cancer nude mouse xenograft model was established by injecting MDA-MB-231 cells. The mice were randomly divided into model group, realgar group and capecitabine tablet group. Hematoxylin and eosin (HE), immunohistochemistry, Western blot and qPCR were used to observe the effect of realgar on epithelial-mesenchymal transition (EMT) of breast cancer. At the same time, the indexes of blood routine, liver and kidney function were detected. RESULTS External using realgar could induce necrosis of breast cancer tissue, the tumor inhibitory rate was 30.2%. Compared with the model group, the liver and kidney functions and blood routine tests of nude mice in realgar group were not significantly abnormal; The immunohistochemical results of tumor tissues suggested that realgar could enhance the expression of E-cadherin and reduce the expression of Vimentin; The results of Western blot and qPCR showed that realgar could enhance the expression of E-cadherin and reduce the expressions of Twist1 and TGF-β1 in tumor tissues (P < 0.05). CONCLUSION External using realgar can inhibit the growth of triple negative breast cancer and regulate EMT by increasing the expression of E-cadherin and decreasing the expressions of Vimentin, Twist1 and TGF-β1. -
Key words:
- realgar /
- external therapy /
- breast cancer /
- epithelial-mesenchymal transition
-
表 1 分组及干预措施
Table 1. Grouping and interventions
组别 n 干预措施 模型组 8 无菌去离子水0.2 mL·d-1, 灌胃。 雄黄外用组 8 0.5 g·mL-1醋调雄黄肿瘤处外敷, 约1 mm厚度,采用纱布包扎固定,8 h·d-1。 卡培他滨片
组8 第2~3周, 第5~6周: 7.8 mg·mL-1卡培他滨片混悬液0.2 mL·d-1, 灌胃;第1周, 第4周: 无菌去离子水0.2 mL·d-1, 灌胃。 表 2 引物序列
Table 2. Primer sequences
引物名称 正向序列(5'→3') 反向序列(5'→3') TGF-β1 TACAGCAACAATTCCTGGCGATACC CTCAACCACTGCCGCACAACTC Vimentin CCTTCGTGAATACCAAGACCTGCTC AATCCTGCTCTCCTCGCCTTCC CDH1 CTGATTCTGCTGCTCTTGCTGTTTC CGTCCTCTTCTCCGCCTCCTC GAPDH TGACTTCAACAGCGACACCCA CACCCTGTTGCTGTAGCCAAA Twist1 CCTCGGACAAGCTGAGCAAGATTC GTCGCTCTGGAGGACCTGGTAG Slug CTGTGACAAGGAATATGTGAGC CTAATGTGTCCTTGAAGCAACC -
[1] MAIRIN O, HARRY C, TONY F, et al. Interventions for raising breast cancer awareness in women[J]. Cochrane Database Syst Rev, 2017, 2: CD011396. doi: 10.1111/ijn.12582 [2] LIU X, LI JJ, CADILHA BL, et al. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis[J]. Sci Adv, 2019, 5(6): eaav4275. [3] KHALED N, BIDET Y. New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer[J]. Cancers, 2019, 11(4): 559. doi: 10.3390/cancers11040559 [4] FOLKMAN J. The role of angiogenesis in tumor growth[J]. Semin Cancer Biol, 1992, 3(2): 65-71. https://www.sciencedirect.com/science/article/pii/S0093775402700651 [5] GOODMAN CR, SEAGLE BLL, FRIEDL TWP, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer[J]. JAMA Oncol, 2018, 4(8): e180163. https://www.scholars.northwestern.edu/en/publications/association-of-circulating-tumor-cell-status-with-benefit-of-radi [6] LIU F, GU LN, SHAN BE, et al. Biomarkers for EMT and MET in breast cancer: An update[J]. Oncol Lett, 2016, 12(6): 4869-4876. doi: 10.3892/ol.2016.5369 [7] 吴晓龙, 徐瑞荣, 沈明月, 等. 徐瑞荣治疗骨髓增殖性肿瘤经验[J]. 辽宁中医杂志, 2019, 46(5): 944-946. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201905015.htmWU XL, XU RR, SHEN MY, et al. Professor XU Ruirong's experience in treatment of myeloproliferative neoplasms[J]. Liaoning J Tradit Chin Med, 2019, 46(5): 944-946. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY201905015.htm [8] 裴可, 齐元富, 李运伦, 等. 中西医结合治疗恶性肿瘤体表破溃创面进展[J]. 中华中医药杂志, 2019, 34(12): 5790-5792. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201912073.htmPEI K, QI YF, LI YL, et al. Research progress of combination of Chinese and western medicine for the treatment of malignant tumor rupture wound[J]. China J Tradit Chin Med Pharm, 2019, 34(12): 5790-5792. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201912073.htm [9] 王春晖. 二硫化二砷和粉防己碱对三阴性乳腺癌联合作用的研究[D]. 北京: 北京中医药大学, 2018.WANG CH. Study on the combined effect of arsenic disulfide and tetrandrine on triple negative breast cancer[D]. Beijing: Beijing University of Chinese Medicine, 2018. [10] 王洪图. 黄帝内经灵枢白话解[M]. 北京: 人民卫生出版社, 2004: 491.WANG HT. The Vernacular Explanation for The Yellow Emperor's Inner Classic: The Spiritual Pivot[M]. Beijing: People's medical publishing house, 2004: 491. [11] 杨群柳, 全建峰. 中医外治法治疗恶性肿瘤及其相关病症的研究进展[J]. 江苏中医药, 2022, 54(2): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202202024.htmYANG QL, QUAN JF. Review of treatment of malignant tumors and related diseases with external therapies in Chinese medicine[J]. Jiangsu J Tradit Chin Med, 2022, 54(2): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202202024.htm [12] 李琦玮, 于明薇, 王笑民. 癌毒理论研究现状[J]. 中医杂志, 2015, 56(4): 347-350, 354. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201504030.htmLI QW, YU MW, WANG XM. Research status of cancer toxin theory[J]. J Tradit Chin Med, 2015, 56(4): 347-350, 354. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201504030.htm [13] 李慧杰, 齐元富, 李秀荣. 基于癌毒理论探讨攻毒治法抗肿瘤转移[J]. 中医药信息, 2018, 35(4): 81-83.LI HJ, QI YF, LI XR. Exploration of anti-tumor metastasis by therapeutics of eliminating toxin based on theory of cancer toxin[J]. Inf Tradit Chin Med, 2018, 35(4): 81-83. [14] 郑文利, 李慧杰, 裴可, 等. 基于癌毒理论探讨攻毒类中药在恶性肿瘤治疗中的应用[J]. 中医药信息, 2019, 36(4): 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN201904028.htmZHENG WL, LI HJ, PEI K, et al. Chinese medicinal of counteracting toxic substances in the treatment of malignant tumor based on cancer toxin theory[J]. Inf Tradit Chin Med, 2019, 36(4): 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN201904028.htm [15] 李经纬, 余瀛鳌, 蔡景峰, 等. 中医大辞典[M]. 北京: 人民卫生出版社, 1995: 397.LI JW, YU YA, CAI JF, et al. Dictionary of Traditional Chinese Medicine[M]. Beijing: People's medical publishing house, 1995: 397. [16] HYAFIL F, BABINET C, JACOB F. Cell-cell interactions in early embryogenesis: A molecular approach to the role of calcium[J]. Cell, 1981, 26(3): 447-454. https://www.sciencedirect.com/science/article/pii/0092867481902142 [17] YANG L, WANG XW, ZHU LP, et al. Significance and prognosis of epithelial-cadherin expression in invasive breast carcinoma[J]. Oncol Lett, 2018, 16(2): 1659-1665. https://www.spandidos-publications.com/ol/16/2/1659 [18] ESLAMI AMIRABADI H, TUERLINGS M, HOLLESTELLE A, et al. Characterizing the invasion of different breast cancer cell lines with distinct E-cadherin status in 3D using a microfluidic system[J]. Biomed Microdevices, 2019, 21(4): 101. [19] HUGO HJ, GUNASINGHE NPAD, HOLLIER BG, et al. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: Oncogenic rather than tumor-suppressive role of E-cadherin[J]. Breast Cancer Res, 2017, 19(1): 86. doi: 10.1186/s13058-017-0880-z [20] PATEL NA, PATEL PS, VORA HH. Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma[J]. Breast Dis, 2015, 35(2): 113-127. https://content.iospress.com/articles/breast-disease/bd395 [21] NIETO MA. The snail superfamily of zinc-finger transcription factors[J]. Nat Rev Mol Cell Biol, 2002, 3(3): 155-166. https://www.nature.com/articles/nrm757/ [22] YANG J, MANI SA, DONAHER JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis[J]. Cell, 2004, 117(7): 927-939. https://www.sciencedirect.com/science/article/pii/S0092867404005768 [23] THIERY JP, SLEEMAN JP. Complex networks orchestrate epithelial-mesenchymal transitions[J]. Nat Rev Mol Cell Biol, 2006, 7(2): 131-142. https://www.nature.com/articles/nrm1835 [24] ZHENG H, KANG Y. Multilayer control of the EMT master regulators[J]. Oncogene, 2014, 33(14): 1755-1763. https://www.nature.com/articles/onc2013128 -